Michael Baram
Michael Baram has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Abjihit Duggal
Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA
1 shared publication- Caleb Chan
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
1 shared publication Carl B. Shanholtz
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
1 shared publication- Clayton H. Brown
The University of Maryland Institute for Health Computing, 6116 Executive Blvd, North Bethesda, MD, 20852
1 shared publication Dan Knox
Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, UT, USA
1 shared publicationFaith Armstrong
Baltimore Washington Medical Center, Glen Burnie, MD, USA
1 shared publication
Latest Publications
- Open Access
- 17 May 2023
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 33, 101155
Design and rationale of the CHILL phase II trial of hypothermia and neuromuscular blockade for acute respiratory distress syndrome
- 17 May 2023
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 33, 101155
Open AccessDesign and rationale of the CHILL phase II trial of hypothermia and neuromuscular blockade for acute respiratory distress syndrome
- Open Access
- 28 June 2018
- Published by Springer Nature
- p. 61-77
Risk Communication Between Companies and Local Stakeholders for Improving Accident Prevention and Emergency Response
- 28 June 2018
- Published by Springer Nature
- p. 61-77
Open AccessRisk Communication Between Companies and Local Stakeholders for Improving Accident Prevention and Emergency Response
- Open Access
- 1 January 2001
- Published by Cambridge University Press (CUP) in American Journal of Law & Medicine
- Vol. 27 (2-3) , 253-282
Making Clinical Trials Safer for Human Subjects
The pace of medical innovation is quickening, pushed by advances in biotechnology and pulled by growing demand for healthcare. Completion of the Human Genome Project has provided a multitude of data for determining genes and their functions, and stimulated the application of information technology and private capital for the development of new individualized drugs, gene therapies, and biomaterials for tissue and organ regeneration. Concurrently, demand for healthcare continues to grow, expanding the market for medical innovations that are proven in clinical trials to be safe and effective.
- 1 January 2001
- Published by Cambridge University Press (CUP) in American Journal of Law & Medicine
- Vol. 27 (2-3) , 253-282
Open AccessMaking Clinical Trials Safer for Human Subjects
The pace of medical innovation is quickening, pushed by advances in biotechnology and pulled by growing demand for healthcare. Completion of the Human Genome Project has provided a multitude of data for determining genes and their functions, and stimulated the application of information technology and private capital for the development of new individualized drugs, gene therapies, and biomaterials for tissue and organ regeneration. Concurrently, demand for healthcare continues to grow, expanding the market for medical innovations that are proven in clinical trials to be safe and effective.